CG Oncology, Inc. ( ($CGON) ) has released its Q4 earnings. Here is a breakdown of the information CG Oncology, Inc. presented to its investors.

Scotiabank initiated coverage of CG Oncology (CGON) with a Sector Perform rating and $23 price target The company is developing a novel ...

Cretostimogene shows promising efficacy in bladder cancer treatment, with 75.5% complete response rate and sustained duration of over 28 months. CG Oncology, Inc. announced encouraging results ...

CG Oncology’s primary focus has been on advancing ... Targeted approach: The specificity of oncolytic viruses in targeting cancer cells while sparing healthy tissue could potentially result ...

Additionally, CG Oncology will present updates to ongoing clinical trials evaluating cretostimogene across the non-muscle invasive bladder cancer (NMIBC) treatment landscape which are expected to ...

CG Oncology also has a Phase 2 trial ... backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit ...

CG Oncology’s primary focus has been on advancing Creto through ... Targeted approach: The specificity of oncolytic viruses in targeting cancer cells while sparing healthy tissue could potentially ...